Loading…
Loading grant details…
| Funder | European Commission |
|---|---|
| Recipient Organization | Stemmatters, Biotecnologia E Mediciina Regenerativa Sa |
| Country | Portugal |
| Start Date | Apr 01, 2023 |
| End Date | Jun 30, 2027 |
| Duration | 1,551 days |
| Number of Grantees | 6 |
| Roles | Associated Partner; Participant; Coordinator |
| Data Source | European Commission |
| Grant ID | 101099867 |
Although immunotherapy of select hematological malignancies using Chimeric Antigen Receptor (CAR) redirected T lymphocytes has recently gained regulatory approval, successful treatment of solid tumors using CAR T cells remains elusive. One salient problem is the limited efficacy and untimely exhaustion of CAR T cells in the tumor microenvironment (TME).
Combining innovative methods of genome editing, chemistry and immunology, CAR T-REX proposes to explore a novel concept of building auto-regulated genetic circuits into CAR T cells to selectively circumvent their exhaustion upon activation in the TME.
Genetic rewiring will be achieved by precisely inserting artificial miRNAs under endogenous exhaustion-related Driver promoters to downregulate Target genes that cause exhaustion. Proprietary technology enables specific replacement of the Driver gene without risking off-target mutations.
Further advantages of combined insertion and silencing are (i) the ability to regulate when a gene is turned on/off by biologically and clinically relevant cellular cues, and (ii) multiple gene-knockdown with a single dsDNA cleavage and RNA-silencing of both alleles.
These genetic modifications will be implemented using a novel high-performance peptide-based gene delivery platform with unlimited loading capacity, allowing combination of several types of cargo, as well as economical large scale GMP production.
Rewired HER2/Neu (ErbB2) redirected CAR T cells will be tested on preclinical breast and gastric carcinomas, and variants that eliminate tumors resistant to conventional 2nd and 3rd generation peers (without adverse events) will be developed/manufactured following quality-by-design principles under GMP-like conditions, thus accelerating the pathway towards clinical translation.
These approaches will also constitute a proof-of-concept for modifying therapeutic cell products, with the potential to considerably improve their safety, specificity, efficacy, scalability and cost.
Debreceni Egyetem; Universidad de Santiago de Compostela; Stemmatters, Biotecnologia E Mediciina Regenerativa Sa; Targetgene Biotechnologies Ltd; Stiftung Leibniz-Institut Fur Immuntherapie
Complete our application form to express your interest and we'll guide you through the process.
Apply for This Grant